BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19129074)

  • 1. A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer.
    Lin RB; Fan NF; Guo ZQ; Wang XJ; Liu J; Chen L
    J Chemother; 2008 Dec; 20(6):744-8. PubMed ID: 19129074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
    Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
    Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
    Mohammad HA; Magdy FM; Mahmoud OM
    Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer.
    Lin R; Fan N; Wu G; Chen Y; Guo Z; Wang X; Jin F; Chen L; Liu J
    J Chemother; 2015 Feb; 27(1):52-6. PubMed ID: 24964957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
    Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
    J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
    Cho YH; Kim SY; Hong Lee M; Yoo MW; Bang HY; Lee KY; Yoon SY
    Gastric Cancer; 2012 Oct; 15(4):389-95. PubMed ID: 22237658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
    Xiang XJ; Liu YW; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
    Anticancer Drugs; 2012 Jun; 23(5):561-6. PubMed ID: 22481063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Seo BG; Kim SH; Kim JS; Kim HJ
    Acta Oncol; 2007; 46(3):336-41. PubMed ID: 17450469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Louvet C; André T; Tigaud JM; Gamelin E; Douillard JY; Brunet R; François E; Jacob JH; Levoir D; Taamma A; Rougier P; Cvitkovic E; de Gramont A
    J Clin Oncol; 2002 Dec; 20(23):4543-8. PubMed ID: 12454110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
    De Vita F; Orditura M; Matano E; Bianco R; Carlomagno C; Infusino S; Damiano V; Simeone E; Diadema MR; Lieto E; Castellano P; Pepe S; De Placido S; Galizia G; Di Martino N; Ciardiello F; Catalano G; Bianco AR
    Br J Cancer; 2005 May; 92(9):1644-9. PubMed ID: 15856038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Al-Batran SE; Atmaca A; Hegewisch-Becker S; Jaeger D; Hahnfeld S; Rummel MJ; Seipelt G; Rost A; Orth J; Knuth A; Jaeger E
    J Clin Oncol; 2004 Feb; 22(4):658-63. PubMed ID: 14966088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer.
    Zhao JG; Qiu F; Xiong JP; Zhang L; Xiang XJ; Yu F; Yan J; Zhan ZY; Feng M
    Anticancer Drugs; 2009 Apr; 20(4):281-6. PubMed ID: 19247179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
    Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
    Oh SY; Kwon HC; Lee S; Lee DM; Yoo HS; Kim SH; Jang JS; Kim MC; Jeong JS; Kim HJ
    Jpn J Clin Oncol; 2007 Dec; 37(12):930-5. PubMed ID: 18211984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.